Paraguay vs Timor-Leste: Average cost of multi drug-resistant tuberculosis treatment
Paraguay
11,664 constant 2022 US$
in 2024
Timor-Leste
50,471 constant 2022 US$
in 2024
Paraguay rank
5th
Timor-Leste rank
2nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Paraguay
- Timor-Leste
How they compare
Timor-Leste currently reports 50,471 constant 2022 US$ against 11,664 constant 2022 US$ in Paraguay, a difference of 38,807 constant 2022 US$.
That makes Timor-Leste's figure about 4.3 times Paraguay's.
The two have swapped places 3 times across 7 shared years of data; in 2017 it was Paraguay ahead.
Paraguay ranks 5th and Timor-Leste ranks 2nd of 92 countries.
Across the 2 decades both report, Paraguay averaged higher in 1 and Timor-Leste in 1.
Head to head by decade
| Decade | Paraguay | Timor-Leste | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,559 constant 2022 US$ | 1,816 constant 2022 US$ | 743.33 constant 2022 US$ | Paraguay |
| 2020s | 4,347 constant 2022 US$ | 13,106 constant 2022 US$ | 8,758 constant 2022 US$ | Timor-Leste |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Paraguay or Timor-Leste?
- Timor-Leste, at 50,471 constant 2022 US$ against 11,664 constant 2022 US$ in Paraguay as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Paraguay and Timor-Leste?
- 38,807 constant 2022 US$, with Timor-Leste ahead.
- How many years of comparable data are there for Paraguay and Timor-Leste?
- 7 years are reported by both, from 2017 to 2024.
- How do Paraguay and Timor-Leste rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Paraguay ranks 5th and Timor-Leste ranks 2nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.